|
Key targets and mechanistic insights affecting radiotherapy effectiveness in renal carcinoma patients with concurrent renal failure
|
J. Wei   , P. Gao , Z. Wang , L. Fan , J. Zhao |
| Department of Nephrology, Zibo First Hospital, Zibo Shandong, China , zhaojin8490@dingtalk.com |
|
|
Abstract: (204 Views) |
Background: To explore the key targets and regulatory mechanisms affecting the efficacy of radiotherapy (RT) in patients with renal carcinoma (RCC) complicated by renal failure. Materials and Methods: Differentially expressed genes (DEGs)(|log2FC|>2) in TCGA (n=537) and GEO data set (n=215) were screened by limma package in R software. Intersecting genes were accessed through the online site (InteractiVenn). The STRING and MCODE module of the Metascape website were used for key target screening and enriched pathway analysis. The preprocessCore R package was used for data normalization and batch effect processing. The survival/survminer R package was used to analyze the relationship between gene expression and patient survival. Results: High expression of ACADM, DLAT, SUCLA2 and SUCLG2 genes were all associated with significantly improved prognosis in renal cancer patients. The mOS time in the ACADM high expression group was 7.10 years [Hazard Ratio (HR) = 0.466, 95% Confidence Interval (CI): 0.353-0.615). The mOS time in the DLAT high expression group was 7.10 years (HR=0.489, 95% CI: 0.372-0.642). The mOS time in the SUCLA2 high expression group was 7.30 years (HR=0.458, 95% CI: 0.346-0.606). The mOS time in the SUCLG2 group was 7.00 years (HR=0.544, 95% CI: 0.415-0.715). Conclusion: The suppression of ACADM, DLAT, SUCLA2, and SUCLG2 can regulate fatty acid metabolism and tricarboxylic acid cycle-related pathways, which provides ideas for the prognosis of patients with RCC complicated by renal failure. |
|
| Keywords: Prognosis, radiotherapy, renal carcinoma, renal failure. |
|
|
Full-Text [PDF 1054 kb]
(55 Downloads)
|
|
Type of Study: Original Research |
Subject:
Radiation Biology
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
